Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
PARP inhibitors for germline BRCA1 or BRCA2 variants
10 evidence topics · 9 sources
PARP inhibitor recommendations in second-line treatment: ESMO 2026 guideline
PARP inhibitor recommendation for hormone receptor-positive disease: ASCO 2021 guideline
PARP inhibitors versus nonplatinum chemotherapy in BRCA1/2 carriers: ASCO, ASTRO, and SSO 2020 guideline
“Platinum agents are recommended versus taxanes to treat advanced BC in BRCA carriers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib and talazoparib) are preferable to nonplatinum single-agent chemotherapy for treatment of advanced BC in BRCA1/2 carriers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator regulatory information: olaparib
Comparator regulatory information: talazoparib
Prevalence of germline BRCA1 or BRCA2 variants in breast cancer: OlympiAD final analysis
“Approximately 5% of all breast cancer patients carry a germline deleterious mutation in BRCA1 and/or BRCA2 (BRCAm), with higher rates among those with human epidermal growth factor receptor 2 (HER2)-negative disease” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Olaparib versus chemotherapy: OlympiAD progression-free survival, response, and safety
“Of the 302 patients who underwent randomization, 205 were assigned to receive olaparib and 97 were assigned to receive standard therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was significantly longer in the olaparib group than in the standard-therapy group (7.0 months vs. 4.2 months; hazard ratio for disease progression or death, 0.58; 95% confidence interval, 0.43 to 0.80; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The response rate was 59.9% in the olaparib group and 28.8% in the standard-therapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The rate of grade 3 or higher adverse events was 36.6% in the olaparib group and 50.5% in the standard-therapy group, and the rate of treatment discontinuation due to toxic effects was 4.9% and 7.7%, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Olaparib versus chemotherapy: OlympiAD final overall survival
“At 64% data maturity, median OS was 19.3 months with olaparib versus 17.1 months with TPC (HR 0.90, 95% CI 0.66–1.23; P = 0.513); median follow-up was 25.3 and 26.3 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“receptor status (triple negative: 0.93, 0.62–1.43; hormone receptor positive: 0.86, 0.55–1.36)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While there was no statistically significant improvement in OS with olaparib compared to TPC, there was the possibility of meaningful OS benefit among patients who had not received chemotherapy for metastatic disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Talazoparib versus chemotherapy: EMBRACA progression-free survival, response, and safety
“Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Talazoparib versus chemotherapy: EMBRACA final overall survival
“As the population was either triple-negative or hormone receptor-positive within EMBRACA, the effect of talazoparib on OS in these two subgroups was generally consistent, with HR 0.899 (95% CI 0.634–1.276) for triple-negative patients and HR 0.827 (95% CI 0.597–1.143) for hormone receptor-positive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Altogether, a similar percentage of patients received subsequent systemic antineoplastic therapy in the talazoparib and chemotherapy groups (80.8% and 76.4%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote